HuagongsheHuagongshe Chemistry Print Report · For research reference only
4-(2-Methoxypropan-2-yl)piperidine → 4-(2-chloro-8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine
Participants
| Role | Name | HCID | Charge |
|---|---|---|---|
| Reactant | 4-(2-Methoxypropan-2-yl)piperidine | HCID 59352871 | — |
| Reactant | 4-(8-(bromomethyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine | HCID 59603481 | — |
| Product | 4-(2-chloro-8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine | HCID 59605726 | 98.3% |
Reaction Steps
4-(2-methoxypropan-2-yl)piperidine (0.12 g) was reacted with 4-(8-(bromomethyl)-2-chloro-9-methyl-9H-purin-6-yl)morpholine (0.25 g) via General Procedure E to give 300 mg of crude 4-(2-chloro-8-((4-(2-methoxypropan-2-yl)piperidin-1-yl)methyl)-9-methyl-9H-purin-6-yl)morpholine, of which 0.78 g was reacted with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-amine via General Procedure A to yield 12 mg of 155 as a white solid following reverse phase purification. MS (Q1) 531.3 (M)+
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| Patent number | US08394796B2 |
| Source dataset | uspto-grants-2013_03 |
| ORD ID | ord-1f50f778be924ae89a7bb8bc69569e74 |
| Source note | uspto-grants-2013_03 |